Get the Stockscreener App
7.17
13.27%
0.84
After Hours:
7.18
0.010
+0.14%
Rocket Pharmaceuticals Inc stock is traded at $7.17, with a volume of 5.18M.
It is up +13.27% in the last 24 hours and down -14.95% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$6.33
Open:
$6.21
24h Volume:
5.18M
Relative Volume:
2.38
Market Cap:
$630.18M
Revenue:
-
Net Income/Loss:
$-258.08M
P/E Ratio:
-2.6073
EPS:
-2.75
Net Cash Flow:
$-202.32M
1W Performance:
+21.32%
1M Performance:
-14.95%
6M Performance:
-59.31%
1Y Performance:
-68.55%
1-Day Range:
$6.21
$7.44
1-Week Range:
$5.90
$7.44
52-Week Range:
$4.55
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
7.17 | 630.18M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Our Attention Has Been Attracted to Rocket Pharmaceuticals Inc (NASDAQ:RCKT) - uspostnews.com
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Alliancebernstein L.P. - Defense World
Geode Capital Management LLC Increases Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
(RCKT) Trading Report - news.stocktradersdaily.com
JPMorgan Chase & Co. Sells 41,024 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
3 Stocks Insiders Are Buying Rapidly Amid Market Volatility - Investing.com
Is Rocket Pharmaceuticals (NASDAQ:RCKT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Countdown To Approval: Rocket Pharma's Gene Therapy For Rare Disease Awaits FDA Decision - RTTNews
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Up After Insider Buying Activity - Defense World
Rocket Pharmaceuticals CEO buys $101.6K in common stock - MSN
Rocket Pharmaceuticals CEO Gaurav Shah acquires $101,600 in stock By Investing.com - Investing.com India
Rocket Pharmaceuticals CEO Gaurav Shah acquires $101,600 in stock - Investing.com Australia
If You Don’t Buy Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Now, You’ll Kick Yourself Later - stocksregister.com
Raymond James Financial Inc. Makes New $285,000 Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating from Needham & Company LLC - Defense World
Rocket Pharmaceuticals executive Kinnari Patel buys $99,165 in stock By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals executive Kinnari Patel buys $99,165 in stock - Investing.com
Rocket Pharma Out Of Orbit, But Ready For Re-Launch (NASDAQ:RCKT) - Seeking Alpha
The Escalator: Rocket Pharmaceuticals, Zenas BioPharma, Angelini Ventures - Medical Marketing and Media
Corebridge Financial Inc. Sells 2,469 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Vanguard Group Inc. Purchases 1,040,655 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple - Insider Monkey
KLP Kapitalforvaltning AS Buys Shares of 15,300 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals CFO sells $39,646 in stock By Investing.com - Investing.com India
Rocket Pharmaceuticals CFO sells $39,646 in stock - Investing.com
Rocket Pharmaceuticals CFO Sells Shares to Cover Tax Obligations - TradingView
10 Stocks Under $10 that Will Triple - Insider Monkey
BMO maintains Rocket Pharmaceuticals Outperform rating By Investing.com - Investing.com UK
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Rocket Pharmaceuticals appoints new Chief Officer By Investing.com - Investing.com Canada
Rocket Pharmaceuticals appoints new Chief Officer - Investing.com Australia
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Genetic Therapy Breakthroughs: Rocket Pharma CEO Set to Reveal Strategic Updates at Major Healthcare Conference - Stock Titan
Thrivent Financial for Lutherans Sells 21,731 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? - MSN
Where are the Opportunities in (RCKT) - news.stocktradersdaily.com
Teacher Retirement System of Texas Raises Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year LowHere's Why - MarketBeat
Swiss National Bank Has $1.93 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Swiss National Bank Buys 29,100 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - The AM Reporter
RCKT Stock Plummets to 52-Week Low, Hits $8.06 Amid Market Struggles - Investing.com UK
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals’ SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
Cantor Fitzgerald maintains Overweight on Rocket Pharmaceuticals stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Has $8.25 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
(RCKT) Technical Pivots with Risk Controls - news.stocktradersdaily.com
PNC Financial Services Group Inc. Increases Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Bank of New York Mellon Corp Buys 9,949 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Fanconi Anemia Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
What technical indicators reveal about RCKT stock - US Post News
Steward Partners Investment Advisory LLC Has $84,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):